Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: () Report Updated: Aug 19, 2017 | Print This Page

Get more stock ratings by Louis Navellier


Rating: Volatility:
Total Grade: Industry:

Stock Analysis

Rating: Monthly View

August September October November December January February March April May June July

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Transition Therapeutics Inc., a biopharmaceutical company, researches and develops therapeutic agents for disease indications primarily in Canada. The company's lead central nervous system drug candidate is ELND005, which has completed a Phase II/III clinical trial for the treatment of agitation/aggression associated with Alzheimer's disease; and has completed Phase IIa clinical trial for the treatment of Down syndrome. Its lead metabolic drug candidate is TT401, which is in Phase II clinical study for the treatment of type 2 diabetes and accompanying obesity. The company is also developing TT701, a selective androgen receptor modulator for the treatment of androgen deficiencies. Transition Therapeutics Inc. has a licensing and collaboration agreement with Eli Lilly to develop and commercialize TT401; and to develop compounds in preclinical models to provide glycemic control and other beneficial effects, including weight loss. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. in December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.